Objective To assess how neonatal intensive care units followed the American Academy of Pediatrics guidelines for use of dexamethasone in preterm infants by evaluating respiratory support at the time of dexamethasone administration.
B
ronchopulmonary dysplasia (BPD) is the most common pulmonary morbidity among premature infants, affecting approximately 22% of all very low birth weight infants (<1500 g birth weight). 1 BPD is associated with increased risk of mortality and morbidity among survivors, including chronic pulmonary disease, pulmonary hypertension, and longterm neurodevelopmental impairment. 2 In a large number of randomized controlled trials, dexamethasone decreased the incidence of BPD, [3] [4] [5] but its use was associated with increased risk of neurodevelopmental impairment and cerebral palsy. 4, 6, 7 Based on these findings, in 2002 the American Academy of Pediatrics (AAP) and the Canadian Pediatric Society issued a joint policy statement advising against the use of dexamethasone for the prevention or treatment of BPD, and recommended limiting the use of dexamethasone to infants on "maximal ventilatory and oxygen support." 8 In this study, we sought to characterize the respiratory status of infants at the time of initiation of dexamethasone.
Methods
In this observational cohort study, we identified very low birth weight (<1500 g birth weight) infants, ≤32 weeks gestational age, admitted from 2003 to 2010 from 290 neonatal intensive care units managed by the Pediatrix Medical Group. We limited the analyses to infants born from 2003 to 2010 to capture clinical practices after the publication of the 2002 AAP guidelines regarding the use of dexamethasone 8 and before the new guidelines were published in 2010. The 2010 guidelines recommended against the use of high-dose dexamethasone but reported insufficient evidence to make any conclusions regarding the use of low-dose dexamethasone. 9 We identified infants who received a course of dexamethasone beginning in the first 120 postnatal days. We excluded any infants missing data describing respiratory support at the time of dexamethasone administration.
Data were obtained from a prospective electronic medical record generated by clinicians on all infants cared for by the Pediatrix Medical Group. Data on multiple aspects of care are entered into the system to produce admission notes, daily progress notes, procedure notes, and discharge summaries. 10 Information collected included demographics, medications (without dose), respiratory support,
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Fraction of inspired oxygen HFV High-frequency ventilator NC Nasal cannula NCPAP Nasal continuous peak airway pressure and diagnoses. This study was approved by the Duke University Institutional Review Board without the need for written informed consent as the data were collected without identifiers. A course of dexamethasone was defined as >1 consecutive day of drug. Only the first course of dexamethasone was analyzed for each infant. Death was defined as death before hospital discharge. Respiratory support and fraction of inspired oxygen (FiO2) were defined at the time of the start of the dexamethasone course as the significant respiratory support and FiO2 observed on either the first day of dexamethasone or the preceding day. We considered both days to describe better the significant respiratory support leading to the clinician decisions to start dexamethasone.
We grouped infants into 4 categories based on respiratory support: (1) no support or oxygen supplementation via hood or tent; (2) nasal cannula (NC), high-flow nasal cannula, or nasal continuous positive airway pressure (NCPAP); (3) conventional mechanical ventilator (CMV); and (4) high-frequency ventilator (HFV). We also categorized infants by the FiO2 required (≤0.3 or >0.3). We grouped infants based on postnatal day they received dexamethasone (<14 or ≥14 days of life), based on AAP guidelines identifying premature infants on the ventilator beyond 2 weeks of life as having a higher risk for BPD. 9 We defined "significant respiratory support" as CMV or HFV and FiO2 > 0.3.
We defined BPD as continuous respiratory support (supplemental oxygen, NC, high-flow NC, NCPAP, CMV, or HFV) between 36 0/7 and 36 6/7 weeks, postmenstrual age. Room air challenge tests were not performed uniformly. Infants who were transferred, discharged, or died before this time were evaluated on their last day of hospitalization; if such an infant was on room air, the infant was defined as not having BPD, and if the infant was on respiratory support (including supplemental oxygen), then the BPD status was defined as "missing."
We calculated the risk of BPD or death using Neonatal Research Network BPD risk estimator (https://neonatal.rti.org/ index.cfm?fuseaction=BPDCalculator.start). 11 This estimator uses gestational age, birth weight, sex, race or ethnicity, postnatal day, ventilator type, and FiO2 to determine an infant's risk of mild, moderate, or severe BPD and death, as defined by the Neonatal Research Network. We estimated the risk of BPD or death based on the calculator's predictions for moderate BPD, severe BPD, or death. The estimator was only validated for infants with gestational age 23-30 weeks, birth weight 501-1249 g, and day of life ≤42, and any infants not meeting these criteria were removed from this particular analysis. The estimator assesses the risk of BPD on postnatal days 1, 3, 7, 14, 21, and 28. We rounded the day of starting dexamethasone to the nearest of these time points, until day of life 43-the day of life at which the estimator is no longer validated, so the calculated BPD risk was defined as "missing." Using the BPD estimator, infants with <50% chance of either death or severe or moderate BPD were defined as infants in which the potential risks of steroid administration outweighed the likely benefits. 12 To assess the efficacy of the BPD risk calculator, we compared predicted incidence of BPD or death with the actual incidence of BPD and death.
Finally, to assess the practices of each site in the Pediatrix Medical Group, we determined the proportion of infants from an individual site receiving dexamethasone on significant support. For this analysis alone, we excluded sites with <10 otherwise eligible infants, as these sites were presumed to have a low patient volume, which could bias the analyses.
Statistical Analyses
We used standard summary statistics (means, percentages, 5th and 95th percentiles) to describe the study variables. Infantlevel continuous and categorical variables were compared using Student t test and c 2 tests, respectively. We used a univariable logistic regression to calculate the ORs and examine the association between admission year and proportion of infants receiving mechanical ventilation upon starting dexamethasone. Infants who received dexamethasone but did not have respiratory data were assumed to be missing at random and excluded from the analysis. All analyses were conducted using Stata 13.1 (StataCorp, College Station, Texas) and assumed a significance level of a = 0.05.
Results
During the study period, 81 292 very low birth weight infants were identified, and 7265 (9%) received dexamethasone (Figure 1 ; available at www.jpeds.com). Of these, 7093 (98%) from 181 sites had respiratory status data available, representing the cohort we analyzed ( Table I ). The first course of dexamethasone began on mean day of life 38 (5th, 95th percentile; 8, 87) with a mean duration of 6 days (2, 15). The first course of dexamethasone was administered after day of life 14 in 6170 (87% of total cohort) infants. At the time of dexamethasone initiation, 4604 (65%) infants were on significant respiratory support (CMV/HFV + > 0.3 FiO2). Of the total cohort, 6064 Volume 183 • April 2017 (85%) of infants were on the ventilator at the start of dexamethasone therapy (Table II) . Between 2003 and 2010, the proportion of infants receiving dexamethasone decreased slightly from 10% to 8%, and the percentage of infants that received significant respiratory support when treated with dexamethasone varied between 60% and 74%. The odds of receiving significant support decreased by 5% (P < .001) for every additional year between 2003 and 2010, with the largest decrease occurring between 2003 and 2004, followed by relatively stable levels thereafter. The odds of receiving >0.3 FiO2 decreased 8% (P < .001) for each additional year. The odds of being ventilated increased by 4% (P = .014) for each additional year.
Using the Neonatal Research Network BPD risk estimator, the risk of BPD or death was calculated for 3661 (52%) of the infants (Figure 2) . Within this group, the mean risk of BPD or death was 77%, and 2343 infants (69%) ultimately were diagnosed with BPD. Comparison of the actual incidence of BPD/ death with predicted incidence by race, sex, respiratory support, FiO2, and age at starting dexamethasone revealed a higher actual incidence for all subgroups, with the exception of infants receiving 0.21 FiO2 and infants receiving dexamethasone <14 days (Table III ; available at www.jpeds.com). Three thousand three hundred seventy-five (92%) infants received dexamethasone when the risk of BPD or death was ≥50%. Of the 286 infants who had a risk <50%, 72 (25%) were on the ventilator, and 15 (5%) were on significant respiratory support.
Among the 180 sites with ≥10 infants that received dexamethasone, there was significant site variation in the level of respiratory support observed; the mean percentage of infants receiving significant support at the time of dexamethasone administration was 58% (range; 0%-100%). One hundred twentynine (72%) of the sites had ≥50% of their infants on significant support at the time of dexamethasone administration, and 21 (12%) of these sites had none of their dexamethasone infants on significant support (Figure 3) .
Discussion
BPD is the most common pulmonary complication for premature infants and is associated with significant morbidity and mortality, including increased risk of neurodevelopmental impairment. [13] [14] [15] [16] Dexamethasone has been shown to reduce the risk of BPD 5, 17, 18 but is associated with neurodevelopmental impairment and cerebral palsy. [19] [20] [21] We used a large database of electronic medical records to determine the levels of respiratory support for infants receiving dexamethasone between 2003 
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and 2010. We found that the majority of the time dexamethasone was used in infants on significant respiratory settings who had an increased risk of BPD, but there were still a number of infants on less than significant respiratory support at the time of dexamethasone administration. In 2002, the AAP recommended that the use of dexamethasone be limited to infants who require significant respiratory support after the first 2 postnatal weeks of age. 8 In our study, approximately one-third of infants were not receiving significant respiratory support at the time of the first day of dexamethasone. Of all infants prescribed dexamethasone, 13% received the drug within the first 2 weeks of life. The proportion of infants receiving dexamethasone with significant respiratory support decreased from 2003 to 2004 and then remained relatively stable from 2004 to 2010. Although this overall proportion on significant respiratory support remained stable during this period, there appeared to be an increase in infants who were ventilated when starting dexamethasone and a corresponding decrease in infants who were on high levels of oxygen support. This increase in the proportion of infants who were ventilated may have partially been influenced by the Dexamethasone: A Randomized Trial study that was published in 2007 and recommended the use of dexamethasone in facilitating extubation. 22 However, the rise we observed was gradual between 2004 and 2010 with no clear spike in 2007 (Figure 4 ; available at www.jpeds.com). In summary, although it appears there were some improvements in following the AAP recommendations reserving dexamethasone for infants on the ventilator, there were increases in the administration of dexamethasone in the setting of low oxygen support.
There may be some infants for whom the risk of BPD is such that the risk-benefit ratio of dexamethasone use favors the use of the drug. A meta-analysis of randomized trials of dexamethasone found that, among infants with a risk of BPD >65%, there was a statistically significant benefit for dexamethasone on the endpoint of death or cerebral palsy. 12 Infants with >50% risk of BPD were likely to benefit from dexamethasone therapy. 12, 23 Among infants for whom the BPD risk estimator could be used, 8% of infants had a BPD risk <50% when they received dexamethasone, and the majority of these were not on significant respiratory support. Comparing the predicted BPD risk to the actual risk of BPD, by race, sex, respiratory support, and start time of dexamethasone, the actual incidences of BPD/death were mostly higher than the predicted incidences. However, this analysis was limited by the fact that the risk estimator could only be used for one-half of the cohort (Table IV ; available at www.jpeds.com). In comparison with the infants for whom the calculator could be used, the infants for whom BPD risk could not be calculated were older when they started dexamethasone, with older gestational ages and higher mean birth weights. They also had lower percentages of ventilator use (21% were nonventilated, compared with 8%) and lower FiO2 (34% had FiO2 ≤ 0.3, compared with 20%) suggesting possibly lower risk of BPD at time of dexamethasone administration (Table V; available at www.jpeds.com). Furthermore, the much older age at dexamethasone administration (54 vs 24 days) suggests decreased utility in using dexamethasone to prevent BPD.
To identify whether dexamethasone administration to infants on significant support varied among sites, we examined the number of infants on significant support by neonatal intensive care unit. At a majority of the sites, over one-half of the infants receiving dexamethasone were on significant support, at 28% of the sites less than one-half were on significant support, and at 12% of the sites none of the infants were on significant support. Thus, adherence to the published AAP guidelines was variable among the sites.
This study reports the respiratory status of infants receiving dexamethasone after the 2002 AAP guidelines. It is limited by a lack of information about the indication for dexamethasone administration. To address this, we excluded any 1-day courses of dexamethasone because these may have been administered to assist extubation or treat upper airway obstruction. It is also possible that clinicians could have administered dexamethasone for purposes other than prevention of BPD, such as vasopressor-resistant hypotension. 24 This study is also limited by a lack of information on dexamethasone dose. In 2010, the AAP modified the guidelines, reporting that high-dose dexamethasone should not be used and that there was insufficient evidence to make a recommendation about the use of low-dose dexamethasone. 9 Even though the updated 2010 AAP guidelines acknowledge that some studies support the use of low-dose corticosteroids to facilitate extubation, they still advised further study of long-term risks before widespread usage of low-dose dexamethasone is recommended. 9 As revealed by the Dexamethasone: A Randomized Trial study, 22 it is possible that administering the correct dose to high-risk infants reduces mortality and improves neurodevelopmental outcomes. Pharmacokinetic and safety studies of dexamethasone are needed to identify the optimal dose, and at this time, any usage of dexamethasone for the purpose of preventing BPD, even low-dose, is not advised for infants on minimal respiratory support.
In summary, this retrospective cohort study of very low birth weight infants receiving dexamethasone demonstrates that although a large majority of infants received care in adherence to the AAP recommendations, there are still a substantial number of infants with less than significant respiratory settings or at low risk of developing BPD who received dexamethasone. Further research in optimizing the use (dose, duration, etc) of dexamethasone is needed to reduce BPD and improve developmental outcomes. ■ For each subgroup, the number of infants from the cohort for whom BPD risk could be calculated are listed , followed by the number of infants from the total cohort. Statistics above represent means (5th, 95th percentile) or percentages.
